Enovix Shares Struggle Despite Record Revenue Figures

Enovix posted record 2025 revenue, but its stock is near a 52-week low as manufacturing bottlenecks delay smartphone battery certification to 2027.

Battery technology firm Enovix posted record quarterly revenue to close out 2025, yet investor sentiment remains decidedly bearish. The market's focus has shifted away from top-line growth to pressing concerns over manufacturing bottlenecks and delayed certifications in the crucial smartphone sector. Shareholders are now questioning how the company plans to convert its ambitious scaling strategy into tangible profitability.

Operational Hurdles Overshadow Financial Performance

A significant disconnect exists between Enovix's financial results and its stock performance. The company's shares are trading just marginally above a 52-week low of €4.18, established the prior week. This stagnation comes despite the company surpassing its own forecasts, reporting Q4 2025 revenue of $11.3 million and full-year revenue of $31.8 million. The primary cause is a series of concrete operational challenges.

Central to these issues is the company's Fab2 production facility in Malaysia. Optimization processes, particularly concerning the laser cutting of battery cells, are proving problematic. Consequently, the critical qualification process for smartphone batteries with major customers is now projected for late 2026 or even 2027.

Strategic Pivot and Financial Resilience

To bridge this anticipated gap, Enovix is pivoting toward other market segments. Current business is being driven largely by defense contracts and rising demand for batteries powering smart glasses. The latter face substantially lower technical certification barriers and are slated for high-volume delivery beginning in the second half of 2026.

Despite near-term headwinds, the company maintains a strong financial position. It entered 2026 with a robust cash balance of $621 million and has authorized a new $75 million share repurchase program. This provides a considerable financial cushion for the costly scaling phase ahead.

Wall Street Adjusts Targets Amid Uncertainty

The delays in mass production have prompted several Wall Street analysts to revise their outlooks downward in the days following the earnings report, citing an uncertain timeline:

• Craig-Hallum: Reduced target from $16 to $10
• Canaccord Genuity: Lowered target from $21 to $15
• B. Riley: Downgraded target from $17 to $10

Management's guidance for Q1 2026 has further tempered expectations. The company anticipates a sequential revenue decline to between $6.5 million and $7.5 million, alongside an operational loss of approximately $30 million. Additional geopolitical risks are noted, as Asian supply chains and production sites remain vulnerable to ongoing trade tensions between the U.S. and China.

The coming months are critical for Enovix. The management team must demonstrate it can swiftly resolve the production issues in Malaysia. The next major indicator will be the Q1 2026 results, expected in late April. The company will need to show that the forecasted quarterly revenue dip is attributable solely to seasonal effects and the timing of defense contracts, while also providing evidence of measurable progress in manufacturing scale-up.